Published in Cell on November 03, 1995
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A (1996) 3.93
Prostaglandins and cancer. Gut (2005) 3.44
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest (2001) 3.01
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A (1998) 2.83
Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A (1996) 2.75
Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol (1997) 2.71
Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut (1999) 2.62
Apoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest (1998) 2.32
The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog (2011) 2.30
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck (2008) 2.28
Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest (2000) 2.27
Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer (2001) 2.26
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Beta-catenin--a linchpin in colorectal carcinogenesis? Am J Pathol (2002) 2.18
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 2.00
Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys (2009) 1.91
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res (2002) 1.90
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A (1996) 1.88
Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A (2000) 1.85
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) (2011) 1.85
Cellular and molecular aspects of gastric cancer. World J Gastroenterol (2006) 1.84
Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst (2015) 1.77
Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci U S A (1998) 1.77
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol (2002) 1.76
Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut (2002) 1.74
Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest (1997) 1.70
Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med (2003) 1.69
Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest (1997) 1.68
Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A (1998) 1.62
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A (2002) 1.61
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A (1999) 1.60
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer (2004) 1.59
P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J (2002) 1.48
Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med (1999) 1.48
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol (2002) 1.46
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol (2000) 1.42
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis (1999) 1.42
Resveratrol: French paradox revisited. Front Pharmacol (2012) 1.40
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer (2005) 1.39
Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease. Mediators Inflamm (2016) 1.39
Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med (2006) 1.38
Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem (2001) 1.36
NF-kappaB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages. Mol Biol Cell (1999) 1.33
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia (2001) 1.32
Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis (2006) 1.32
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab (2001) 1.31
Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer (2000) 1.31
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci U S A (2003) 1.30
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol (2000) 1.27
Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest (1997) 1.25
Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors. Carcinogenesis (2010) 1.23
Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol (2005) 1.22
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer (1999) 1.22
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A (2011) 1.21
Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A (2001) 1.21
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res (2005) 1.21
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res (2002) 1.20
Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol (2005) 1.18
Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer (2006) 1.18
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res (2008) 1.17
Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer (2003) 1.16
Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest (2000) 1.16
Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. Gut (2001) 1.16
Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol (2014) 1.15
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol (2006) 1.13
Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction (2003) 1.12
Mechanisms linking obesity and cancer. Biochim Biophys Acta (2013) 1.12
Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol (2000) 1.12
EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat (2007) 1.11
New isolation technique to study apoptosis in human intestinal epithelial cells. Am J Pathol (1998) 1.10
Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer (2004) 1.10
Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol (2012) 1.09
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 1.08
Cyclooxygenase-2 inhibits UVB-induced apoptosis in mouse skin by activating the prostaglandin E2 receptors, EP2 and EP4. Cancer Res (2007) 1.08
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07
Aberrant crypt foci as microscopic precursors of colorectal cancer. World J Gastroenterol (2003) 1.07
Carcinogenesis and chemoprevention of biliary tract cancer in pancreaticobiliary maljunction. World J Gastrointest Oncol (2010) 1.06
Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am J Pathol (2007) 1.06
Prostaglandin E2 increases hematopoietic stem cell survival and accelerates hematopoietic recovery after radiation injury. Stem Cells (2013) 1.05
Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition. PLoS One (2011) 1.05
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res (2012) 1.04
Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ Health Perspect (2006) 1.04
Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer (2004) 1.04
The Role of Inflammation in the Pathogenesis of Colorectal Cancer. Curr Colorectal Cancer Rep (2009) 1.04
COX-2 and cancer: a new approach to an old problem. Br J Pharmacol (2001) 1.02
APOBEC-1-mediated RNA editing. Wiley Interdiscip Rev Syst Biol Med (2010) 1.02
A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine. Ghana Med J (2013) 1.01
Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int J Cancer (2009) 1.01
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia (2007) 1.01
The down-regulation of Notch1 inhibits the invasion and migration of hepatocellular carcinoma cells by inactivating the cyclooxygenase-2/Snail/E-cadherin pathway in vitro. Dig Dis Sci (2012) 1.01
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem (1997) 2.66
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res (2000) 2.05
Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol (1996) 1.91
Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem (2000) 1.77
Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology (2000) 1.75
Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology (1996) 1.65
Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol (1997) 1.63
Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem (2000) 1.58
Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem (2001) 1.48
Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation. J Biol Chem (2001) 1.43
A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology (1997) 1.35
The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer (1995) 1.32
Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest (1997) 1.25
Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem (1998) 1.24
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog (1999) 1.23
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res (1997) 1.23
Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene (2001) 1.20
Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys (1995) 1.20
Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem (2001) 1.20
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia (2001) 1.18
Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis (1998) 1.16
Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci (1998) 1.15
Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology (2000) 1.13
Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem (1992) 1.12
Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology (1998) 1.11
Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res (1998) 1.09
Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem (2000) 1.09
Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol (1997) 1.09
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis (1999) 1.07
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res (2001) 1.04
The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). Biochemistry (1995) 1.03
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia (2001) 0.99
Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia (2001) 0.98
Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem (2001) 0.98
Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis (1998) 0.97
Molecular cloning, expression, and enzymatic characterization of the rat kidney cytochrome P-450 arachidonic acid epoxygenase. J Biol Chem (1993) 0.96
The role of COX-2 in intestinal cancer. Ann N Y Acad Sci (1999) 0.96
Induction of synthesis of cholesterol side chain cleavage cytochrome P-450 by adrenocorticotropin in cultured bovine adrenocortical cells. J Biol Chem (1981) 0.95
Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Differ (1997) 0.94
Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep (1999) 0.93
Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia (1999) 0.90
Eicosanoids and the large intestine. Prostaglandins Other Lipid Mediat (2000) 0.89
Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene (1999) 0.88
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res (1997) 0.88
Evidence for a higher molecular weight precursor of cholesterol side-chain-cleavage cytochrome P-450 and induction of mitochondrial and cytosolic proteins by corticotropin in adult bovine adrenal cells. Proc Natl Acad Sci U S A (1981) 0.88
Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2. Gastroenterology (1998) 0.86
The role of COX-2 in intestinal cancer. Expert Opin Investig Drugs (1999) 0.84
Combinations for cancer prevention. Nat Med (2000) 0.84
Regulation of 12-lipoxygenase in rat intestinal epithelial cells during differentiation and apoptosis induced by sodium butyrate. Arch Biochem Biophys (1999) 0.82
Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am (2001) 0.82
In vivo immediate early gene expression induced in intestinal and colonic mucosa by feeding. FEBS Lett (1991) 0.81
Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer. Ann N Y Acad Sci (2000) 0.81
Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells. Oncogene (2011) 0.80
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer (2003) 0.80
The molecular basis for prevention of colorectal cancer. Clin Colorectal Cancer (2001) 0.80
Regulation of cyclo-oxygenase-2. Best Pract Res Clin Gastroenterol (2001) 0.79
Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. Gastroenterology (1995) 0.79
The molecular basis of colorectal carcinogenesis. Curr Opin Gastroenterol (1999) 0.77
Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol (2000) 0.77
Antioxidant effect of acetaminophen in rat liver. Biochem Pharmacol (1983) 0.76
Cyclooxygenease-2 and hepatocellular carcinoma: is it a target for prevention? Clin Cancer Res (2001) 0.75
Induction of rabbit cyclooxygenase 2 in the anterior uvea following glaucoma filtration surgery. Curr Eye Res (1997) 0.75
Altered heme environments in opossum and rabbit methemoglobins. Z Naturforsch C (1982) 0.75
Current concepts in colorectal cancer prevention. Compr Ther (1997) 0.75